Paul Tudor Jones Celldex Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$35.22 - $51.88 $1.86 Million - $2.74 Million
52,842 Added 363.38%
67,384 $2.83 Million
Q4 2023

Feb 14, 2024
SELL
$22.61 - $40.65 $169,484 - $304,712
-7,496 Reduced 34.01%
14,542 $576,000
Q3 2023

Nov 15, 2023
SELL
$25.45 - $37.46 $41,661 - $61,322
-1,637 Reduced 6.91%
22,038 $606,000
Q2 2023

Aug 14, 2023
SELL
$30.29 - $38.28 $109,044 - $137,808
-3,600 Reduced 13.2%
23,675 $803,000
Q1 2023

May 15, 2023
BUY
$34.78 - $47.43 $948,624 - $1.29 Million
27,275 New
27,275 $981,000

Others Institutions Holding CLDX

# of Institutions
207
Shares Held
67.3M
Call Options Held
1.69M
Put Options Held
980K
View Full List

About Celldex Therapeutics, Inc.

CLDX Quotes by TradingView
  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.22B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email